

Bernard Combe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9097137/publications.pdf>

Version: 2024-02-01

286
papers

37,045
citations

7568

77
h-index

3106

187
g-index

317
all docs

317
docs citations

317
times ranked

22903
citing authors

#	ARTICLE	IF	CITATIONS
1	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010, 62, 2569-2581.	6.7	6,781
2	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.9	3,366
3	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1580-1588.	0.9	2,994
4	Treating rheumatoid arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 631-637.	0.9	1,711
5	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 492-509.	0.9	1,688
6	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 964-975.	0.9	1,429
7	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 3-15.	0.9	1,114
8	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Arthritis and Rheumatism</i> , 2011, 63, 573-586.	6.7	864
9	American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 404-413.	0.9	657
10	EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCSIT). <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 34-45.	0.9	651
11	Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. <i>Arthritis and Rheumatism</i> , 2008, 58, 3319-3329.	6.7	539
12	2016 update of the EULAR recommendations for the management of early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 948-959.	0.9	393
13	Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. <i>Arthritis Research and Therapy</i> , 2008, 10, R30.	3.5	387
14	Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 120-126.	0.9	382
15	Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 2006, 54, 2807-2816.	6.7	354
16	Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry. <i>Arthritis and Rheumatism</i> , 2010, 62, 2458-2466.	6.7	352
17	Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 913-920.	0.9	349
18	Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. <i>Lancet, The</i> , 2018, 391, 2513-2524.	13.7	316

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1629-1635.	0.9	296
20	Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. <i>Arthritis and Rheumatism</i> , 2010, 62, 2625-2632.	6.7	266
21	Effect of Methotrexate, Anti-Tumor Necrosis Factor $\hat{\pm}$, and Rituximab on the Immune Response to Influenza and Pneumococcal Vaccines in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. <i>Arthritis Care and Research</i> , 2014, 66, 1016-1026.	3.4	248
22	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , 2010, 62, 2582-2591.	6.7	246
23	Prognostic factors for radiographic damage in early rheumatoid arthritis: A multiparameter prospective study. <i>Arthritis and Rheumatism</i> , 2001, 44, 1736-1743.	6.7	239
24	Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52-week clinical trial of sulphasalazine and methotrexate compared with the single components. <i>Annals of the Rheumatic Diseases</i> , 1999, 58, 220-225.	0.9	227
25	COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e419-e426.	3.9	211
26	EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 491-496.	0.9	209
27	The DESIR cohort: A 10-year follow-up of early inflammatory back pain in France: Study design and baseline characteristics of the 708 recruited patients. <i>Joint Bone Spine</i> , 2011, 78, 598-603.	1.6	204
28	EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 851-858.	0.9	204
29	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 638-643.	0.9	203
30	Tumour necrosis factor $\hat{\text{A}}$ blocking agents in refractory adult Still's disease: an observational study of 20 cases. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 262-266.	0.9	193
31	Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1026-1031.	0.9	193
32	Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. <i>Journal of Rheumatology</i> , 1999, 26, 7-13.	2.0	182
33	Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2014, 371, 1781-1792.	27.0	169
34	Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 98-103.	0.9	164
35	The ESPOIR cohort: A ten-year follow-up of early arthritis in France. <i>Joint Bone Spine</i> , 2007, 74, 440-445.	1.6	161
36	Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. <i>Rheumatology</i> , 2011, 50, 222-229.	1.9	159

#	ARTICLE	IF	CITATIONS
37	Remission and rheumatoid arthritis: Data on patients receiving usual care in twenty-four countries. <i>Arthritis and Rheumatism</i> , 2008, 58, 2642-2651.	6.7	156
38	Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Induces Rheumatoid Arthritis Synovial Fibroblast Proliferation through Mitogen-activated Protein Kinases and Phosphatidylinositol 3-Kinase/Akt. <i>Journal of Biological Chemistry</i> , 2005, 280, 15709-15718.	3.4	152
39	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Methodological Report Phase I. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1589-1595.	0.9	152
40	Interleukin-2 in rheumatoid arthritis: production of and response to interleukin-2 in rheumatoid synovial fluid, synovial tissue and peripheral blood. <i>Clinical and Experimental Immunology</i> , 1985, 59, 520-8.	2.6	148
41	Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. <i>Lancet, The</i> , 2016, 388, 2763-2774.	13.7	144
42	Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 862-868.	0.9	143
43	Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors. <i>Arthritis and Rheumatology</i> , 2019, 71, 599-611.	5.6	142
44	A report of 21 cases of rheumatoid arthritis following Chikungunya fever. A mean follow-up of two years. <i>Joint Bone Spine</i> , 2009, 76, 654-657.	1.6	135
45	Regulatory B10 Cells Are Decreased in Patients With Rheumatoid Arthritis and Are Inversely Correlated With Disease Activity. <i>Arthritis and Rheumatology</i> , 2014, 66, 2037-2046.	5.6	132
46	B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: A six-month, national, multicenter, open-label study. <i>Arthritis and Rheumatism</i> , 2011, 63, 933-938.	6.7	129
47	Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2006, 73, 388-395.	1.6	126
48	Maintenance of infliximab treatment in ankylosing spondylitis: Results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. <i>Arthritis and Rheumatism</i> , 2008, 58, 88-97.	6.7	126
49	Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 987-994.	0.9	126
50	Bone Mineral Density of 704 Amateur Sportsmen Involved in Different Physical Activities. <i>Osteoporosis International</i> , 2001, 12, 152-157.	3.1	125
51	Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 848-858.	0.9	123
52	Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the OrenCIA and Rheumatoid Arthritis™ registry. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1815-1819.	0.9	117
53	Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis. <i>Joint Bone Spine</i> , 2014, 81, 287-297.	1.6	115
54	EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 479-481.	0.9	114

#	ARTICLE	IF	CITATIONS
55	Non-drug treatment (excluding surgery) in rheumatoid arthritis: Clinical practice guidelines. <i>Joint Bone Spine</i> , 2009, 76, 691-698.	1.6	107
56	Radiological damage in patients with rheumatoid arthritis on sustained remission. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 358-363.	0.9	106
57	Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 675-680.	0.9	105
58	Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1357-1362.	0.9	102
59	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 482-492.	0.9	102
60	Tumor Necrosis Factor- α Blockers in SAPHO Syndrome: Table 1.. <i>Journal of Rheumatology</i> , 2010, 37, 1699-1704.	2.0	100
61	Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study. <i>Arthritis Research and Therapy</i> , 2008, 10, R106.	3.5	99
62	Recommendations of the French Society for Rheumatology regarding TNF α antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. <i>Joint Bone Spine</i> , 2007, 74, 638-646.	1.6	98
63	Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: Data from the French Autoimmunity and Rituximab registry. <i>Arthritis Care and Research</i> , 2010, 62, 1787-1795.	3.4	97
64	Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 1998, 57, 110-113.	0.9	93
65	A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1430-1435.	0.9	93
66	Clinical presentation of patients suffering from recent onset chronic inflammatory back pain suggestive of spondyloarthritis: The DESIR cohort. <i>Joint Bone Spine</i> , 2015, 82, 345-351.	1.6	92
67	Update of French society for rheumatology recommendations for managing rheumatoid arthritis. <i>Joint Bone Spine</i> , 2019, 86, 135-150.	1.6	90
68	SULPHASALAZINE IN PSORIATIC ARTHRITIS: A RANDOMIZED, MULTICENTRE, PLACEBO-CONTROLLED STUDY. <i>Rheumatology</i> , 1996, 35, 664-668.	1.9	89
69	Glucocorticoids in rheumatoid arthritis: current status and future studies. <i>RMD Open</i> , 2020, 6, e000536.	3.8	89
70	Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis. <i>Joint Bone Spine</i> , 2014, 81, 6-14.	1.6	85
71	Operational definition of Active and Healthy Ageing (AHA): A conceptual framework. <i>Journal of Nutrition, Health and Aging</i> , 2015, 19, 955-960.	3.3	85
72	Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 694-700.	0.9	83

#	ARTICLE	IF	CITATIONS
73	How to predict prognosis in early rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 137-146.	3.3	81
74	Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2011, 63, 3692-3701.	6.7	81
75	Influence of replacing tuberculin skin test with ex vivo interferon \hat{I}^3 release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1783-1790.	0.9	81
76	Early rheumatoid arthritis: strategies for prevention and management. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007, 21, 27-42.	3.3	79
77	Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. <i>Joint Bone Spine</i> , 2014, 81, 215-221.	1.6	79
78	Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 1993, 20, 1129-32.	2.0	79
79	Anti-heat shock protein 70 kDa and 90 kDa antibodies in serum of patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 1999, 58, 291-296.	0.9	78
80	Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 799-804.	0.9	78
81	Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: Data from the Étude et Suivi des Polyarthrites		

#	ARTICLE	IF	CITATIONS
91	Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort. <i>Arthritis Research and Therapy</i> , 2009, 11, R114.	3.5	62
92	Risk of fracture and low bone mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis. <i>Osteoporosis International</i> , 2018, 29, 2389-2397.	3.1	62
93	Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort. <i>Arthritis Research and Therapy</i> , 2012, 14, R249.	3.5	61
94	Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. <i>Journal of Rheumatology</i> , 2001, 28, 173-81.	2.0	61
95	Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature. <i>Rheumatology</i> , 2015, 54, 915-926.	1.9	60
96	A proliferation inducing ligand (APRIL) promotes IL-10 production and regulatory functions of human B cells. <i>Journal of Autoimmunity</i> , 2016, 73, 64-72.	6.5	60
97	Increased percentage of cd3+, cd57+ lymphocytes in patients with rheumatoid arthritis. correlation with duration of disease. <i>Arthritis and Rheumatism</i> , 1993, 36, 608-612.	6.7	58
98	Nonpharmacological treatments in early rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2006, 73, 396-402.	1.6	58
99	Evaluation of Serum Interleukin-6 Level as a Surrogate Marker of Synovial Inflammation and as a Factor of Structural Progression in Early Rheumatoid Arthritis: Results From a French National Multicenter Cohort. <i>Arthritis Care and Research</i> , 2015, 67, 905-912.	3.4	55
100	Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 518-526.	0.9	54
101	Rheumatoid arthritis after Chikungunya fever: a prospective follow-up study of 21 cases: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1505-1506.	0.9	53
102	Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 724-729.	0.9	52
103	Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1797-1802.	0.9	52
104	Treatment of rheumatoid arthritis with methotrexate: a prospective open longterm study of 191 cases. <i>Journal of Rheumatology</i> , 1991, 18, 1323-7.	2.0	52
105	Level of agreement of the 1987 ACR and 2010 ACR/EULAR rheumatoid arthritis classification criteria: an analysis based on ESPOIR cohort data. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 386-389.	0.9	50
106	Recommendations of the French Society for Rheumatology. TNF antagonist therapy in rheumatoid arthritis. <i>Joint Bone Spine</i> , 2006, 73, 433-441.	1.6	49
107	Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry. <i>Rheumatology</i> , 2016, 55, 874-882.	1.9	49
108	Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE. <i>Rheumatology</i> , 2017, 56, 1746-1754.	1.9	49

#	ARTICLE	IF	CITATIONS
109	Predictors of radiographic progression in the ESPOIR cohort: the season of first symptoms may influence the short-term outcome in early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1251-1256.	0.9	47
110	Understanding emerging treatment paradigms in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2011, 13, S3.	3.5	46
111	Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 967-975.	3.4	46
112	Arthritis after infection with Chikungunya virus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 337-346.	3.3	45
113	Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2094-2100.	0.9	45
114	The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2005, 23, 795-800.	0.8	45
115	Physical examination and laboratory tests in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2005, 72, 222-228.	1.6	43
116	Non-pharmacological and pharmacological interventions in patients with early arthritis: a systematic literature review informing the 2016 update of EULAR recommendations for the management of early arthritis. <i>RMD Open</i> , 2017, 3, e000404.	3.8	43
117	Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the EULAR recommendations for the management of early arthritis. <i>RMD Open</i> , 2017, 3, e000406.	3.8	41
118	Rapid Improvement in the Signs and Symptoms of Rheumatoid Arthritis Following Certolizumab Pegol Treatment Predicts Better Longterm Outcomes: Post-hoc Analysis of a Randomized Controlled Trial. <i>Journal of Rheumatology</i> , 2011, 38, 990-996.	2.0	39
119	Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice. <i>Joint Bone Spine</i> , 2014, 81, 352-359.	1.6	39
120	Association of Tobacco Exposure and Reduction of Radiographic Progression in Early Rheumatoid Arthritis: Results From a French Multicenter Cohort. <i>Arthritis Care and Research</i> , 2013, 65, 1899-1906.	3.4	38
121	Five-year Favorable Outcome of Patients with Early Rheumatoid Arthritis in the 2000s: Data from the ESPOIR Cohort. <i>Journal of Rheumatology</i> , 2013, 40, 1650-1657.	2.0	38
122	Chikungunya Virus-Associated Disease. <i>Current Rheumatology Reports</i> , 2017, 19, 69.	4.7	38
123	Efficacy and Safety of Rituximab in Elderly Patients With Rheumatoid Arthritis Enrolled in a French Society of Rheumatology Registry. <i>Arthritis Care and Research</i> , 2014, 66, 1289-1295.	3.4	37
124	Reasons for non-vaccination in French rheumatoid arthritis and spondyloarthritis patients. <i>Rheumatology</i> , 2015, 54, 748-750.	1.9	37
125	High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis. <i>Rheumatology</i> , 2015, 54, 601-608.	1.9	36
126	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 963-969.	0.9	36

#	ARTICLE	IF	CITATIONS
127	Rheumatoid nodulosis: report of two new cases and discussion of diagnostic criteria. <i>Journal of Rheumatology</i> , 1988, 15, 1427-30.	2.0	36
128	Psychological distress over time in early rheumatoid arthritis: results from a longitudinal study in an early arthritis cohort. <i>Rheumatology</i> , 2015, 54, 520-527.	1.9	34
129	Efficacy and safety of biological DMARDs modulating B cells in primary Sjögren's syndrome: Systematic review and meta-analysis. <i>Joint Bone Spine</i> , 2018, 85, 15-22.	1.6	34
130	First-Year Radiographic Progression as a Predictor of Further Progression in Early Arthritis: Results of a Large National French Cohort. <i>Arthritis Care and Research</i> , 2013, 65, 1907-1915.	3.4	33
131	Structural evaluation in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2005, 72, 229-234.	1.6	32
132	Early lessons from the recent-onset rheumatoid arthritis cohort ESPOIR. <i>Joint Bone Spine</i> , 2015, 82, 13-17.	1.6	32
133	TNF- α antagonist therapy in ankylosing spondylitis and psoriatic arthritis: recommendations of the French Society for Rheumatology. <i>Joint Bone Spine</i> , 2006, 73, 547-553.	1.6	31
134	Early referral to the rheumatologist for early arthritis patients: evidence for suboptimal care. Results from the ESPOIR cohort. <i>Rheumatology</i> , 2010, 49, 147-155.	1.9	31
135	Hormonal replacement therapy may reduce the risk for RA in women with early arthritis who carry HLA-DRB1 *01 and/or *04 alleles by protecting against the production of anti-CCP: results from the ESPOIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1683-1686.	0.9	29
136	Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials. <i>Journal of Rheumatology</i> , 2016, 43, 1063-1067.	2.0	29
137	Polymorphism of the HLA-DMA and DMB genes in Rheumatoid Arthritis. <i>Arthritis and Rheumatism</i> , 1997, 40, 854-858.	6.7	28
138	Ability of oblique foot radiographs to detect erosions in early arthritis: Results in the ESPOIR cohort. <i>Arthritis and Rheumatism</i> , 2008, 59, 1729-1734.	6.7	27
139	Validation of ACR/EULAR definition of remission in rheumatoid arthritis from RA practice: the ESPOIR cohort. <i>Arthritis Research and Therapy</i> , 2012, 14, R156.	3.5	27
140	Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 14.	3.5	27
141	Effect of adherence to European treatment recommendations on early arthritis outcome: data from the ESPOIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1803-1808.	0.9	26
142	Prediction of Remission in a French Early Arthritis Cohort by RAPID3 and other Core Data Set Measures, but Not by the Absence of Rheumatoid Factor, Anticitrullinated Protein Antibodies, or Radiographic Erosions. <i>Journal of Rheumatology</i> , 2016, 43, 1285-1291.	2.0	26
143	Should patients with recent-onset polyarthritis receive aggressive treatment?. <i>Joint Bone Spine</i> , 2004, 71, 475-480.	1.6	25
144	Can Remission in Rheumatoid Arthritis Be Assessed Without Laboratory Tests or a Formal Joint Count? Possible Remission Criteria Based on a Self-report RAPID3 Score and Careful Joint Examination in the ESPOIR Cohort. <i>Journal of Rheumatology</i> , 2013, 40, 386-393.	2.0	25

#	ARTICLE	IF	CITATIONS
145	Identification of secreted phosphoprotein 1 gene as a new rheumatoid arthritis susceptibility gene. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e19-e19.	0.9	24
146	Targeting the Fas/FasL system in Rheumatoid Arthritis therapy: Promising or risky?. <i>Cytokine</i> , 2015, 75, 228-233.	3.2	24
147	Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 3738-3746.	1.9	24
148	Relative Clinical Influence of Clinical, Laboratory, and Radiological Investigations in Early Arthritis on the Diagnosis of Rheumatoid Arthritis. Data from the French Early Arthritis Cohort ESPOIR. <i>Journal of Rheumatology</i> , 2010, 37, 2486-2492.	2.0	23
149	Rheumatoid Arthritis of the Hand: Monitoring with a Simplified MR Imaging Scoring Methodâ€”Preliminary Assessment. <i>Radiology</i> , 2010, 256, 863-869.	7.3	23
150	Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1477-1486.	0.9	23
151	Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort. <i>Arthritis Research and Therapy</i> , 2019, 21, 140.	3.5	23
152	The DIGICOD cohort: A hospital-based observational prospective cohort of patients with hand osteoarthritisâ€”A methodology and baseline characteristics of the population. <i>Joint Bone Spine</i> , 2021, 88, 105171.	1.6	23
153	Choice of secondâ€line diseaseâ€modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: A decision tree for clinical practice based on rheumatologists' preferences. <i>Arthritis and Rheumatism</i> , 2009, 61, 425-434.	6.7	21
154	Mechanisms and clinical relevance of TRAILâ€triggered responses in the synovial fibroblasts of patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2011, 63, 904-913.	6.7	21
155	Prevalence and concordance of early and sustained remission assessed by various validated indices in the early arthritis â€œESPOIRâ€ cohort. <i>Joint Bone Spine</i> , 2014, 81, 409-415.	1.6	21
156	Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohort. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 2054-2060.	0.9	21
157	Relevance and feasibility of a systematic screening of multimorbidities in patients with chronic inflammatory rheumatic diseases. <i>Joint Bone Spine</i> , 2019, 86, 49-54.	1.6	21
158	Evaluation of the impact of a nurse-led program of patient self-assessment and self-management in axial spondyloarthritis: results of a prospective, multicentre, randomized, controlled trial (COMEDSPA). <i>Rheumatology</i> , 2021, 60, 888-895.	1.9	21
159	Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab. <i>Rheumatology</i> , 2016, 55, 1466-1476.	1.9	20
160	Improvement of fatigue in patients with rheumatoid arthritis treated with biologics: relationship with sleep disorders, depression and clinical efficacy. A prospective, multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 85-92.	0.8	20
161	Diagnosis of peripheral psoriatic arthritis: Recommendations for clinical practice based on data from the literature and experts opinion. <i>Joint Bone Spine</i> , 2009, 76, 532-539.	1.6	19
162	Clinical and laboratory follow-up for treating and monitoring patients with ankylosing spondylitis: Development of recommendations for clinical practice based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2007, 74, 330-337.	1.6	18

#	ARTICLE	IF	CITATIONS
163	Defining erosive disease typical of RA in the light of the ACR/EULAR 2010 criteria for rheumatoid arthritis; results of the data driven phase. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 590-595.	0.9	18
164	The effect on treatment response of fibromyalgic symptoms in early rheumatoid arthritis patients: results from the ESPOIR cohort. <i>Rheumatology</i> , 2015, 54, 2166-2170.	1.9	18
165	Association Between Vitamin D Deficiency and Disease Activity, Disability, and Radiographic Progression in Early Rheumatoid Arthritis: The ESPOIR Cohort. <i>Journal of Rheumatology</i> , 2020, 47, 1624-1628.	2.0	18
166	Switching between anti-TNF α agents: what is the evidence?. <i>Joint Bone Spine</i> , 2004, 71, 169-171.	1.6	17
167	Association of Anticyclic Citrullinated Peptide Antibodies and/or Rheumatoid Factor Status and Clinical Presentation in Early Arthritis: Results from the ESPOIR Cohort. <i>Journal of Rheumatology</i> , 2014, 41, 1614-1622.	2.0	17
168	Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study. <i>RMD Open</i> , 2015, 1, e000037.	3.8	17
169	Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts. <i>RMD Open</i> , 2015, 1, e000128.	3.8	17
170	Imaging for the diagnosis and follow-up of ankylosing spondylitis: Development of recommendations for clinical practice based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2007, 74, 338-345.	1.6	16
171	Pharmacotherapy (excluding biotherapies) for ankylosing spondylitis: Development of recommendations for clinical practice based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2007, 74, 346-352.	1.6	16
172	Potential Classification Criteria for Rheumatoid Arthritis After Two Years: Results From a French Multicenter Cohort. <i>Arthritis Care and Research</i> , 2013, 65, 1227-1234.	3.4	16
173	Factors associated with a bad functional prognosis in early inflammatory back pain: results from the DESIR cohort. <i>RMD Open</i> , 2016, 2, e000204.	3.8	16
174	A randomised, double-blind, placebo-controlled study assessing the efficacy of high doses of vitamin D on functional disability in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 1056-1060.	0.8	16
175	Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6months' first-line DMARD therapy. <i>Joint Bone Spine</i> , 2007, 74, 73-78.	1.6	15
176	Pharmacological treatment (biotherapy excluded) of peripheral psoriatic arthritis: Development of recommendations for clinical practice based on data from the literature and experts opinion. <i>Joint Bone Spine</i> , 2009, 76, 524-531.	1.6	15
177	The two directions of TNF-related apoptosis-inducing ligand in rheumatoid arthritis. <i>Cytokine</i> , 2013, 63, 81-90.	3.2	15
178	Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data. <i>RMD Open</i> , 2016, 2, e000245.	3.8	15
179	Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept. <i>Rheumatology</i> , 2022, 61, 953-962.	1.9	15
180	Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the $\tilde{\text{ORA}}^{\text{TM}}$ registry. <i>RMD Open</i> , 2017, 3, e000515.	3.8	14

#	ARTICLE	IF	CITATIONS
181	Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis. Expert Review of Clinical Immunology, 2021, 17, 85-100.	3.0	14
182	Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: results from the ESPOIR early synovitis cohort. Rheumatology, 2012, 51, 1648-1654.	1.9	13
183	Repeated Anticitrullinated Protein Antibody and Rheumatoid Factor Assessment Is Not Necessary in Early Arthritis: Results from the ESPOIR Cohort. Journal of Rheumatology, 2014, 41, 41-46.	2.0	13
184	<i>SPP1</i>rs9138 variant contributes to the severity of radiological damage in anti-citrullinated protein autoantibody-negative rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, 1840-1843.	0.9	13
185	Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort. Arthritis Research and Therapy, 2019, 21, 243.	3.5	13
186	An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases. Rheumatology, 2020, 59, 1842-1852.	1.9	13
187	Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials. Arthritis Research and Therapy, 2021, 23, 119.	3.5	13
188	Lymphoma complicating rheumatoid arthritis: results from a French caseâ€“control study. RMD Open, 2021, 7, e001698.	3.8	13
189	GUEPARD treat-to-target strategy is significantly more efficacious than ESPOIR routine care in early rheumatoid arthritis according to patient-reported outcomes and physician global estimate. Rheumatology, 2013, 52, 1890-1897.	1.9	12
190	Biologic Disease-modifying Antirheumatic Drug (bDMARD)-induced Neutropenia: A Registry from a Retrospective Cohort of Patients with Rheumatic Diseases Treated with 3 Classes of Intravenous bDMARD. Journal of Rheumatology, 2017, 44, 844-849.	2.0	12
191	Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib. Annals of the Rheumatic Diseases, 2019, 78, 1135-1138.	0.9	12
192	Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies. Arthritis Research and Therapy, 2021, 23, 41.	3.5	12
193	Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort. Rheumatology, 2021, 60, 5073-5079.	1.9	12
194	Factors determining a DMARD initiation in early inflammatory arthritis patients. The ESPOIR cohort study. Clinical and Experimental Rheumatology, 2009, 27, 84-91.	0.8	12
195	Effects of biologic disease-modifying anti-rheumatic drugs on the radiographic progression of rheumatoid arthritis: a systematic literature review. Clinical and Experimental Rheumatology, 2018, 36, 658-667.	0.8	12
196	Poor efficacy of TNF inhibitors in non-radiographic axial spondyloarthritis in the absence of objective signs: A bicentric retrospective study. Joint Bone Spine, 2018, 85, 461-468.	1.6	11
197	Predictors of fatigue and persistent fatigue in early rheumatoid arthritis: a longitudinal observational study, data from the ESPOIR cohort. Scandinavian Journal of Rheumatology, 2020, 49, 259-266.	1.1	11
198	Evaluation of the impact of a nurse-led program of systematic screening of comorbidities in patients with axial spondyloarthritis: The results of the COMEDSPA prospective, controlled, one year randomized trial. Seminars in Arthritis and Rheumatism, 2020, 50, 701-708.	3.4	11

#	ARTICLE	IF	CITATIONS
199	The Reference Site Collaborative Network of the European Innovation Partnership on Active and Healthy Ageing. <i>Translational Medicine @ UniSa</i> , 2019, 19, 66-81.	0.5	11
200	Update on the use of etanercept across a spectrum of rheumatoid disorders. <i>Biologics: Targets and Therapy</i> , 2008, 2, 165.	3.2	10
201	Recommandations de la Société française de rhumatologie pour la prise en charge de la polyarthrite rhumatoïde. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2014, 81, 303-312.	0.0	10
202	Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry. <i>Rheumatology</i> , 2017, 56, kew476.	1.9	10
203	Management of dyslipidaemia in high-risk patients with recent-onset rheumatoid arthritis: targets still not met despite specific recommendations. Results from the ESPOIR cohort during the first five years of follow-up. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 296-302.	0.8	10
204	Low Influenza, Pneumococcal and Diphtheria/Tetanus/Poliomyelitis Vaccine Coverage in Patients with Primary Sjögren's Syndrome: A Cross-Sectional Study. <i>Vaccines</i> , 2020, 8, 3.	4.4	9
205	Referring early arthritis patients within 6 weeks versus 12 weeks after symptom onset: an observational cohort study. <i>Lancet Rheumatology, The</i> , 2020, 2, e332-e338.	3.9	9
206	TNF inhibitors increase fat mass in inflammatory rheumatic disease: a systematic review with meta-analysis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 337-343.	0.8	9
207	Prognosis and follow-up of psoriatic arthritis with peripheral joint involvement: Development of recommendations for clinical practice based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2009, 76, 540-546.	1.6	8
208	Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study. <i>RMD Open</i> , 2020, 6, e000991.	3.8	8
209	Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2). <i>Rheumatology and Therapy</i> , 2021, 8, 199-217.	2.3	8
210	Cytomegalovirus infection: friend or foe in rheumatoid arthritis?. <i>Arthritis Research and Therapy</i> , 2021, 23, 16.	3.5	8
211	Regression of an expanded subpopulation of large granular lymphocytes in a patient with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1991, 34, 246-247.	6.7	7
212	Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as prognostic factors in rheumatoid arthritis: results from the ESPOIR cohort. <i>Arthritis Research and Therapy</i> , 2015, 17, 193.	3.5	7
213	Clinical association of mixed connective tissue disease and granulomatosis with polyangiitis: a case report and systematic screening of anti-U1RNP and anti-PR3 auto-antibody double positivity in ten European hospitals. <i>Immunologic Research</i> , 2016, 64, 1243-1246.	2.9	7
214	Shifting from a Rheumatologic Point of View toward Patient-centered Care in Rheumatoid Arthritis with an Integrated Management of Comorbidities. <i>Journal of Rheumatology</i> , 2019, 46, 545-547.	2.0	7
215	Risk of Cancer After Initiation of Targeted Therapies in Patients With Rheumatoid Arthritis and a Prior Cancer: Systematic Review With Meta-Analysis. <i>Arthritis Care and Research</i> , 2023, 75, 260-271.	3.4	7
216	The French early arthritis registry. <i>Clinical and Experimental Rheumatology</i> , 2003, 21, S123-8.	0.8	7

#	ARTICLE	IF	CITATIONS
217	Time to initiation of biologic disease-modifying antirheumatic drugs in the French cohort ESPOIR. <i>Joint Bone Spine</i> , 2021, 88, 105060.	1.6	6
218	The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies. <i>Arthritis Research and Therapy</i> , 2022, 24, 11.	3.5	6
219	Cardiovascular events and change in cholesterol levels in patients with rheumatoid arthritis treated with tocilizumab: data from the REGATE Registry. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 501-507.	0.8	6
220	Determining a low disease activity threshold for decision to maintain disease-modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2009, 11, R157.	3.5	5
221	The new classification criteria for rheumatoid arthritis and their impact on therapeutic decisions. <i>Joint Bone Spine</i> , 2011, 78, 539-541.	1.6	5
222	THU0192â€¦5-Year Results from the Rapid 1 Trial and Open-Label Extension: Long-Term Safety and Efficacy of Certolizumab Pegol in Combination with Methotrexate in the Treatment of Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A228.2-A229.	0.9	5
223	Impact of disease activity and treatments on ovarian reserve in patients with rheumatoid arthritis in the ESPOIR cohort. <i>Rheumatology</i> , 2021, 60, 1863-1870.	1.9	5
224	Disease-modifying drug retention rate according to patient age in patients with early rheumatoid arthritis: analysis of the ESPOIR cohort. <i>Rheumatology International</i> , 2021, 41, 879-885.	3.0	5
225	Exploring the disparity between inflammation and disability in the 10-year outcomes of people with rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 4687-4701.	1.9	5
226	Change in MRI in patients with spondyloarthritis treated with anti-TNF agents: systematic review of the literature and meta-analysis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 242-252.	0.8	5
227	Leflunomide combined with conventional disease-modifying antirheumatic drugs or biologics in patients with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2006, 73, 587-590.	1.6	4
228	Diagnostic du rhumatisme psoriasique de forme pÃ©riphÃ©rique : Ã©laboration de recommandations pour la pratique clinique, Ã partir dâ€™une analyse systÃ©matique de la littÃ©rature et de lâ€™opinion dâ€™experts. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2007, 74, 15-22.	0.0	4
229	Value of high-sensitivity C-reactive protein for classification of early axial spondyloarthritis: results from the DÃ©SIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 785-786.	0.9	4
230	Diabetes at the time of rheumatoid arthritis diagnosis is an independent predictor of pejorative outcomes: Data from the early arthritis ESPOIR cohort. <i>Joint Bone Spine</i> , 2018, 85, 773-775.	1.6	4
231	Reduced progression of bone erosion in cytomegalovirus seropositive rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2020, 22, 13.	3.5	4
232	Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results. <i>Clinical Rheumatology</i> , 2022, 41, 3035-3047.	2.2	4
233	Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review. <i>Journal of Rheumatology</i> , 2017, 44, 773-779.	2.0	3
234	EnquÃªte naturaliste sur lâ€™utilisation des anti-inflammatoires non stÃ©roÃ¯diens chez des patients souffrant de douleurs rhumatologiques. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2003, 70, 416-423.	0.0	2

#	ARTICLE	IF	CITATIONS
235	L'Évaluation clinique et biologique dans la prise en charge de personnes souffrant de polyarthrite rhumatoïde de établissement de recommandations pour la pratique clinique À partir de données de la littérature et d'opinions d'experts (Rencontres d'experts en rhumatologie). Revue Du Rhumatisme (Edition Française), 2004, 71, S127-S136.	0.0	2
236	SAT0084...Effects of different steroid doses on adverse events and radiographic progression of certolizumab pegol-treated rheumatoid arthritis patients:. Annals of the Rheumatic Diseases, 2013, 71, 498.2-498.	0.9	2
237	THU0173...Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice: The Maintain Study. Annals of the Rheumatic Diseases, 2013, 72, A221.4-A222.	0.9	2
238	FRI0245...Prospective follow-up of tocilizumab treatment in 1100 patients with refractory rheumatoid arthritis: tolerance data from the french registry regate (registry "roactemra). Annals of the Rheumatic Diseases, 2013, 72, A456.3-A457.	0.9	2
239	FRI0173...Gastrointestinal perforations with certolizumab PEGOL. Annals of the Rheumatic Diseases, 2013, 71, 370.2-370.	0.9	2
240	Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52. Clinical Rheumatology, 2021, 40, 4943-4954.	2.2	2
241	Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure. Annals of the Rheumatic Diseases, 2022, 81, 944-950.	0.9	2
242	Artritis reumatoide: clínica y diagnóstico. EMC - Aparato Locomotor, 2007, 40, 1-17.	0.1	1
243	Response to: "Metabolic and cardiovascular benefits of hydroxychloroquine: exploration in a wider population at high CV risk" by Pareek <i>et al</i>. Annals of the Rheumatic Diseases, 2019, 78, e22-e22.	0.9	1
244	OP0066...Risk of fracture and low mineral density in adults with inflammatory bowel diseases. a systematic literature review with meta-analysis. , 2018, , .		1
245	FRI0106...Impact of biological and targeted synthetic dmards on work in patients with chronic inflammatory arthritis : a meta analysis of randomised controlled trials and controlled cohorts. , 2018, , .		1
246	ESPOIR and the French database management: what have we learned from the first years of follow-up?. Clinical and Experimental Rheumatology, 2014, 32, S-153-7.	0.8	1
247	Cardiovascular events and change in cholesterol levels in patients with rheumatoid arthritis treated with tocilizumab: data from the REGATE Registry. Clinical and Experimental Rheumatology, 2021, 39, 501-507.	0.8	1
248	Change in MRI in patients with spondyloarthritis treated with anti-TNF agents: systematic review of the literature and meta-analysis. Clinical and Experimental Rheumatology, 2021, 39, 242-252.	0.8	1
249	Faut-il traiter de façon agressive une polyarthrite débutante ?. Revue Du Rhumatisme (Edition) Tj ETQq1 1 0.784314 rgBT_Overlo	0.0	0
250	Inmunopatología de la artritis reumatoide. EMC - Aparato Locomotor, 2004, 37, 1-9.	0.1	0
251	Pronostic et suivi du rhumatisme psoriasique de forme psoriasisique : Élaboration de recommandations pour la pratique clinique, À partir d'une analyse systématique de la littérature et de l'opinion d'experts. Revue Du Rhumatisme (Edition Française), 2007, 74, 23-30.	0.0	0
252	Les traitements médicamenteux (hors biothérapie) dans la prise en charge de patients atteints de rhumatisme psoriasique psoriasisique : Élaboration de recommandations pour la pratique clinique, À partir d'une analyse systématique de la littérature et de l'opinion d'experts. Revue Du Rhumatisme (Edition Française), 2007, 74, 31-38.	0.0	0

#	ARTICLE	IF	CITATIONS
253	Arbre d'cisionnel permettant le choix en pratique clinique d'un traitement de fond de seconde intention au cours de la polyarthrite rhumatoïde récente, après le succès d'un traitement de fond de première intention d'une durée de six mois. Revue Du Rhumatisme (Edition Francaise), 2007, 74, 79-84.	0.0	0
254	Critères composites de suivi d'activité dans la polyarthrite rhumatoïde. Revue Du Rhumatisme Monographies, 2010, 77, 17-21.	0.0	0
255	THU0264...In Early Rheumatoid Arthritis (Espoir Cohort), Serum CCL19 Level is Associated with Disease Activity, Autoantibody Secretion and 3-Year Radiographic Progression: Data from the Espoir Cohort. Annals of the Rheumatic Diseases, 2014, 73, 274.2-274.	0.9	0
256	FRIO048...Prevalence of Tuberculosis in Early Arthritis and Early Spondyloarthritis Increased in Comparison to the General Population - Results from the ESPOIR and DESIR Cohorts: Table 1.. Annals of the Rheumatic Diseases, 2014, 73, 398.2-399.	0.9	0
257	Taux de rétention de l'adalimumab, de l'etanercept et de l'infliximab en 1re ou 2e ligne de biothérapie chez les patients atteints de polyarthrite rhumatoïde en pratique courante. Revue Du Rhumatisme (Edition Francaise), 2014, 81, 483-490.	0.0	0
258	Reply to Talarico et al.'s comment: "Rate of serious infections in patients with rheumatoid arthritis receiving tumor necrosis factor (TNF)-alpha antagonist: A prospective observational study". Joint Bone Spine, 2014, 81, 379-380.	1.6	0
259	AB0438...Efficacy and Safety of Tabalumab, an Anti-B Cell Activating Factor Monoclonal Antibody, in Patients with Rheumatoid Arthritis WHO HAD an Inadequate Response to Tnf-Alpha Inhibitors: Results from A Phase 3 Multicenter, Randomized, Double-Blind Study. Annals of the Rheumatic Diseases, 2014, 73, 952.3-953.	0.9	0
260	THU0485...The SPP1 Rs9138 Variant Contributes to the Severity of Radiologic Damage in Acpa-Negative Rheumatoid Arthritis: Results from the ESPOIR and Leiden EAC Cohorts. Annals of the Rheumatic Diseases, 2014, 73, 351.1-351.	0.9	0
261	SAT0048...Identification of Genes Regulating Trail-Induced Apoptosis in Rheumatoid Arthritis Fibroblasts-Like Synoviocytes (RA FLS). Annals of the Rheumatic Diseases, 2015, 74, 665.2-665.	0.9	0
262	Présentation clinique des patients souffrant de rachialgie inflammatoire chronique récente. Revue Du Rhumatisme (Edition Francaise), 2015, 82, 378-385.	0.0	0
263	L'association abatacept plus méthotrexate permet d'atteindre à nouveau la mission, de manière efficace et bien tolérée, après la reprise du traitement pour poussées inflammatoires chez des patients atteints de polyarthrite rhumatoïde récente. Revue Du Rhumatisme (Edition Francaise), 2016, 83, A43-A44.	0.0	0
264	FRIO219...Risk Factors of Severe Infections in Patients with Rheumatoid Arthritis Treated with Tocilizumab in The French Registry Regate (Registry "Roactemra). Annals of the Rheumatic Diseases, 2016, 75, 511.2-511.	0.9	0
265	Comparison of modified disease-activity scores with original composite scores for prediction of structural damages in rheumatoid arthritis: Data from the ESPOIR cohort. Joint Bone Spine, 2017, 84, 111-112.	1.6	0
266	SAT0189...Factors influencing the prescription of tocilizumab alone or in combination with dmards in rheumatoid arthritis patients in a real life setting. pooled analysis of 3 observational studies. , 2017, , .		0
267	Response to: "Cardiovascular effects of hydroxychloroquine: a systematic review and meta-analysis" by Mathieu et al. Annals of the Rheumatic Diseases, 2018, 77, e66-e66.	0.9	0
268	SAT0569...Impact of bariatric surgery on rheumatic diseases: a systematic review and meta-analysis. , 2018, , .		0
269	La présence de diabète lors du diagnostic de la polyarthrite rhumatoïde est un facteur indépendant prédictif de mauvais résultats: données de la cohorte ESPOIR sur les polyarthrites récentes. Revue Du Rhumatisme (Edition Francaise), 2019, 86, 534-536.	0.0	0
270	SAT0151...TIME TO INITIATION OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE FRENCH COHORT ESPOIR. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
271	THU0172â€¦UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS: RESULTS AT 60 WEEKS FROM THE SELECT-BEYOND STUDY. , 2019, , .		0
272	AB0421â€¦METHOTREXATE COMPLIANCE AMONG PATIENTS WITH CHRONIC INFLAMMATORY DISEASE OR CONNECTIVE TISSUE DISEASE. , 2019, , .		0
273	Head-to-head trials in inflammatory arthritis. Joint Bone Spine, 2021, 88, 105004.	1.6	0
274	OP0183â€¦IDENTIFICATION OF A SUBGROUP OF PEOPLE WITH RHEUMATOID ARTHRITIS CHARACTERISED BY HIGH DISABILITY OVER 10 YEARS, DESPITE LOW INFLAMMATION: RESULTS FROM TWO EUROPEAN PROSPECTIVE COHORT STUDIES. Annals of the Rheumatic Diseases, 2021, 80, 110.2-111.	0.9	0
275	POS0658â€¦GEOGRAPHIC VARIATION OF EFFICACY IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM. Annals of the Rheumatic Diseases, 2021, 80, 570-571.	0.9	0
276	POS0657â€¦GEOGRAPHIC VARIATION OF SAFETY IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM. Annals of the Rheumatic Diseases, 2021, 80, 569.2-570.	0.9	0
277	POS0654â€¦IMPACT OF CONCOMITANT GLUCOCORTICOIDS ON THE CLINICAL EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: AN AD HOC ANALYSIS OF DATA FROM THREE PHASE 3 STUDIES. Annals of the Rheumatic Diseases, 2021, 80, 567-568.	0.9	0
278	Lâ€™apport et les indications des biothÃ©rapies dans les rhumatismes inflammatoires. Bulletin De L'Academie Nationale De Medecine, 2012, 196, 1279-1293.	0.0	0
279	THU0207â€¦SUSTAINABILITY OF RESPONSE TO UPADACITINIB AS MONOTHERAPY OR IN COMBINATION AMONG PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DMARDS. Annals of the Rheumatic Diseases, 2020, 79, 327.1-328.	0.9	0
280	FRI0131â€¦SUSTAINABILITY OF RESPONSE BETWEEN UPADACITINIB AND ADALIMUMAB AMONG PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO METHOTREXATE. Annals of the Rheumatic Diseases, 2020, 79, 647.1-648.	0.9	0
281	Lymphoma complicating rheumatoid arthritis: results from a French case-control study. RMD Open, 2021, 7, .	3.8	0
282	Impact of multimorbidity on disease modifying antirheumatic drug therapy in early rheumatoid arthritis: Data from the ESPOIR cohort. Joint Bone Spine, 2022, 89, 105326.	1.6	0
283	Impact of dosing on treatment with TNF inhibitors: managing dose adjustment. Clinical and Experimental Rheumatology, 2010, 28, S13-7.	0.8	0
284	Trajectories in early rheumatoid arthritis related fatigue over 10 years: results from the ESPOIR cohort. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
285	Validation in the ESPOIR cohort of vitamin K-dependent protein S (PROS) as a potential biomarker capable of predicting response to the methotrexate/etanercept combination. Arthritis Research and Therapy, 2022, 24, 72.	3.5	0
286	Positive impact on 10-year outcome of the window of opportunity for conventional synthetic DMARDs in rheumatoid arthritis: results from the ESPOIR cohort. RMD Open, 2022, 8, e002040.	3.8	0